Safety, tolerability and pharmacokinetics of 21 day multiple oral administration of a new oxazolidinone antibiotic, LCB01-0371, in healthy male subjects | Zendy

Yewon Choi | Zendy; Sang Won Lee | Zendy; Anhye Kim | Zendy; Kyungho Jang | Zendy; Hee-Sook Nam | Zendy; Young Lag Cho | Zendy; KyungSang Yu | Zendy; InJin Jang | Zendy; JaeYong Chung | Zendy

Open Access

Safety, tolerability and pharmacokinetics of 21 day multiple oral administration of a new oxazolidinone antibiotic, LCB01-0371, in healthy male subjects

Author(s) -

Yewon Choi,

Sang Won Lee,

Anhye Kim,

Kyungho Jang,

Hee-Sook Nam,

Young Lag Cho,

KyungSang Yu,

InJin Jang,

JaeYong Chung

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx367

Subject(s) - tolerability , pharmacokinetics , placebo , dosing , medicine , adverse effect , antibiotics , urine , pharmacology , anesthesia , chemistry , biochemistry , alternative medicine , pathology

LCB01-0371 is a new oxazolidinone antibiotic, which targets most Gram-positive organisms. High rates of adverse reactions including myelosuppression have been reported for existing oxazolidinones, limiting their long-term use.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research